Clinical Trial Investigator:Danny Bega, MD
Aim: This study will evaluate the efficacy and safety of a medication called WTX101 administered for 24 weeks in newly diagnosed Wilson Disease patients.
The study drug, WTX101 (bis-choline tetrathiomolybdate) is a medication that removes copper from your body and it is being investigated for the treatment of Wilson Disease. The aim of this study is to confirm that the dosing regimen planned for use in late phase studies with WTX101 is safe and effective in removing copper from newly diagnosed Wilson Disease patients. The study will be conducted at 6 Wilson Disease expert centres (3 in the US and 3 in Europe).
Eligibility: You may be eligible to join the trial that is currently underway, if you meet the following criteria:
- Newly diagnosed with Wilson disease
- Male or female, aged 18 years or older
- Have elevated copper levels in the blood
- Treated with chelation (a binding agent that removes copper from the body) or zinc therapy for 28 days or less
- In otherwise general good health (no other major systemic illnesses)
Study Duration: 8 months (32 weeks)
Compensation: Parking voucher will be provided
ALL STUDY RELATED MEDICATION/PROCEDURES ARE FREE OF CHARGE.
For More Information: Call us at (312) 503-2593.
Northwestern Medicine and Northwestern University Feinberg School of Medicine will not release any of your personal information to 3rd parties, participating organizations and/or other institutions. Your information will only be available to the researcher(s) after you indicate interest in being contacted about a particular study.
Newly diagnosed with Parkinson’s disease and not yet treated? Please complete the Northwestern Medicine Parkinson’s Disease and Movement Disorders Center online appointment form to discuss next steps.
Feinberg is not a site of care. PDMDC faculty see patients through our affiliated clinic.